# A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse

> **NCT06643585** · PHASE3 · RECRUITING · sponsor: **Prof. Wolfgang Janni** · enrollment: 180 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab-Deruxtecan
- **OTHER:** Physicians Choice (PhC).

## Key facts

- **NCT ID:** NCT06643585
- **Lead sponsor:** Prof. Wolfgang Janni
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-22
- **Primary completion:** 2032-04-22
- **Final completion:** 2032-04-22
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2025-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06643585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06643585, "A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06643585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*